PixarBio Corporation’s CEO Frank Reynolds to Discuss Non-Opiate/Opioid NeuroRelease on the Pain and Addiction Panel at the 2017 MassBio Annual Meeting in Cambridge, MA on March 31, 2017

PixarBio Corporation’s CEO Frank Reynolds to Discuss Non-Opiate/Opioid NeuroRelease on the Pain and Addiction Panel at the 2017 MassBio Annual Meeting in Cambridge, MA on March 31, 2017

PixarBio Corporation (OTC: PXRB) developers of NeuroRelease^TM, announced Founder and CEO Frank Reynolds will be discussing NeuroRelease, PixarBio’s answer to the opiate war at the 2017 MassBio Annual Meeting as a member of the Panel on Pain & Addiction at the Royal Sonesta Boston, Longfellow Room, in Cambridge, MA, at 8:30am on March 31, 2017.

NeuroRelease is a non-opiate/opioid, non-addictive post-surgical pain treatment with clinical studies planned for 2018 and US FDA approval expected in early 2019.

We all understand the devastation that addiction to opiates and opioids are causing in our society but we cannot eliminate addiction until we discover a non-addictive method for treating pain. The Panel for Pain & Addiction will include the following leaders in the space who will discuss what’s next for pain:

• John J. Renger, Ph.D., Head of Clinical Research, Purdue Pharma L.P.;
• Michio Painter, Co-Founder & CEO, Blue Therapeutics;
• Michael Heffernan, Founder, President & CEO, Collegium Pharmaceutical Inc.;
• Frank Reynolds, Founder & CEO, PixarBio Corporation;
• Anna Christo, Director of Innovation Services, MassBio.

The NeuroRelease ^TM Platform: Non-Addictive and Non-opiate Treatment of Pain
NeuroRelease^TM is a morphine replacement, and non-addictive pain platform for the surgical/hospital setting, for the battlefield, or for acute and chronic pain. First product FDA approval for the platform will be for a 14-day post-surgical pain treatment and it is expected in early 2019.

Major Benefits of NeuroRelease^TM :

• Treats only sensory nerve fibers, or pain signals going back to the brain;
• No effect on locomotion nerve fibers, so patients can enter physical therapy quickly;
• Maintains two-point discriminate touch so patients can function and feel the ground; and
• No effect on proprioception so no effect on a person feeling of well-being.

Therefore, patients will maintain two-point discriminate touch, control of their locomotion nerve fibers so they control voluntary movement to enter rehabilitation quickly with a non-addictive morphine replacement. PixarBio’s NeuroRelease^TM pain platform also includes 3-day, 7-day, and 90-Day pain treatments. NeuroRelease^TM is biodegradable and non-toxic so NeuroRelease^TM can be re-injected for repeat treatments.

PixarBio Corporation was awarded the Boston Business Journal's "2016 Best Places to Work". The award recognizes PixarBio as one of the region's best firms, offering the greatest professional opportunities and work environments to innovate.

About the 2017 Annual MassBio Meeting
The MassBio Annual Meeting focuses on the timeliest and critical challenges facing the Massachusetts life sciences industry. The meeting program is designed by a steering committee of industry leaders and the agenda encompasses keynote presentations, panel discussions, interactive working sessions and extensive networking opportunities. The MassBio Annual Meeting focuses on the timeliest and critical challenges facing the Massachusetts life sciences industry. The meeting program is designed by a steering committee of industry leaders and the agenda encompasses keynote presentations, panel discussions, interactive working sessions and extensive networking opportunities.

About PixarBio Corporation
PixarBio is a public company traded on the OTC markets under the stock symbol PXRB. PixarBio is a specialty pharmaceutical/biotechnology company focused on pre-clinical and clinical commercial development of novel neurological drug delivery systems for post-operative pain. PixarBio researches and develops targeted delivery systems for drugs, devices, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. Our lead product platform, NeuroRelease™, has achieved sustained therapeutic release of non-opiate drugs for post-operative, acute and chronic pain in pre-clinical models. For more information, visit www.pixarbio.com.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements. These statements relate to future events or PixarBio’s future performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of PixarBio or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. PixarBio has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While PixarBio believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the PixarBio’s control. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of Biotech and medical device industry regulation and health care legislation in the United States and internationally; global trends on cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; PixarBio’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of PixarBio’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

PixarBio Corp undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be obtained through PixarBio’s corporate headquarters at 200 Boston Ave, Suite 1875 in Medford, MA 02155.

PixarBio Corporation
Ken Stromsland
617-913-8884
CIO and VP, External Communication & Investor Relations
info@pixarbio.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20170330005978/en/